Back
Compare AU
Compare DRUG vs. ATOM
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Global X Uranium ETF (ATOM). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | ATOM | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 123 |
Median incremental investment | $745.07 | $1,002.89 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,592.71 | $2,606.00 |
Average age group | > 35 | > 35 |
Key Summary
DRUG | ATOM | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | ATOM.AX was created on 2022-12-07 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Global Uranium & Nuclear Components Total Return Index |
Top 3 holdings | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) | Cameco Corp (23.23 %) NexGen Energy Ltd (6.78 %) Oklo Inc Class A Shares (6.62 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Energy (57.48 %) Utilities (16.32 %) Industrials (11.79 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | Canada (41.16 %) United States (28.35 %) Korea (8.72 %) |
Management fee | 0.57 % | 0.69 % |
Key Summary
DRUG | ATOM | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Solactive Global Uranium & Nuclear Components Index |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.69 % |
Price | $8.54 | $26.06 |
Size | $176.672 million | $144.725 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.92 % | 1.97 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 06/12/2022 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | ATOM | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 123 |
Median incremental investment | $745.07 | $1,002.89 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,592.71 | $2,606.00 |
Average age group | > 35 | > 35 |
Pros and Cons
DRUG | ATOM | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | ATOM |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |